Published in Hum Pathol on May 01, 1993
A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas. J Clin Pathol (1995) 3.79
Somatic mutations in the p53 gene and prognosis in breast cancer: a meta-analysis. Br J Cancer (1999) 2.36
Breast carcinomas occurring in young women (< 35 years) are different. Br J Cancer (1996) 1.57
Pathological and biological features of mammographically detected invasive breast carcinomas. Br J Cancer (1995) 1.54
Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer (1995) 1.40
Problems with p53 immunohistochemical staining: the effect of fixation and variation in the methods of evaluation. Br J Cancer (1994) 1.37
Beta-catenin up-regulates the expression of cyclinD1, c-myc and MMP-7 in human pancreatic cancer: relationships with carcinogenesis and metastasis. World J Gastroenterol (2005) 1.26
Preoperative assessment of prognostic factors in breast cancer. J Clin Pathol (2001) 1.23
Including total EGFR staining in scoring improves EGFR mutations detection by mutation-specific antibodies and EGFR TKIs response prediction. PLoS One (2011) 1.21
H19 overexpression in breast adenocarcinoma stromal cells is associated with tumor values and steroid receptor status but independent of p53 and Ki-67 expression. Am J Pathol (1998) 1.19
p53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results. Br J Cancer (1994) 1.07
The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma. Br J Cancer (1994) 1.03
Mad2 and p53 expression profiles in colorectal cancer and its clinical significance. World J Gastroenterol (2003) 0.99
Barrett's esophagus. The significance of p53 in clinical practice. Ann Surg (1997) 0.93
Serum antibodies against p53 in relation to cancer risk and prognosis in breast cancer: a population-based epidemiological study. Br J Cancer (1999) 0.92
Immunostaining of thymidylate synthase and p53 for predicting chemoresistance to S-1/cisplatin in gastric cancer. Br J Cancer (2007) 0.91
Evaluation of p53 protein expression as a marker for long-term prognosis in colorectal carcinoma. Br J Cancer (1995) 0.90
Mad2 and p27 expression profiles in colorectal cancer and its clinical significance. World J Gastroenterol (2004) 0.88
p53 protein as a prognostic indicator in breast carcinoma: a comparison of four antibodies for immunohistochemistry. Br J Cancer (1996) 0.88
Human thyroid cancer cells as a source of iso-genic, iso-phenotypic cell lines with or without functional p53. Br J Cancer (1999) 0.87
p53 expression in carcinoma of the cervix. J Clin Pathol (1996) 0.87
TP53 mutation analyses on breast carcinomas: a study of paraffin-embedded archival material. Br J Cancer (1996) 0.86
Prognostic significance of p53 overexpression in primary breast cancer; a novel luminometric immunoassay applicable on steroid receptor cytosols. Br J Cancer (1995) 0.86
Relationship between the expression of human telomerase reverse transcriptase gene and cell cycle regulators in gastric cancer and its significance. World J Gastroenterol (2003) 0.85
p53 mutation in breast cancer. Correlation with cell kinetics and cell of origin. J Clin Pathol (2002) 0.84
Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. Br J Cancer (1997) 0.84
P53 protein in 204 patients with primary breast carcinoma--immunohistochemical detection and clinical value as a prognostic factor. Arch Gynecol Obstet (1995) 0.84
The Risk Factors Influencing between the Early and Late Recurrence in Systemic Recurrent Breast Cancer. J Breast Cancer (2012) 0.83
Prognostic significance of immunohistochemical expression of p53 gene product in operable breast cancer. Cancer Res Treat (2006) 0.83
Expression of the cell cycle regulatory proteins p34cdc2, p21waf1, and p53 in node negative invasive ductal breast carcinoma. Mol Pathol (2003) 0.82
Grade of recurrent in situ and invasive carcinoma following treatment of pure ductal carcinoma in situ of the breast. Br J Cancer (2004) 0.80
Allelic imbalance at chromosome 17p13.3 (YNZ22) in breast cancer is independent of p53 mutation or p53 overexpression and is associated with poor prognosis at medium-term follow-up. Br J Cancer (1998) 0.79
Prevalence of HER-2 and Hormone Receptors and P53 Mutations in the Pathologic Specimens of Breast Cancer Patients. Int J Breast Cancer (2014) 0.79
Prognostic indicators in a range of astrocytic tumours: an immunohistochemical study with Ki-67 and p53 antibodies. J Neurol Neurosurg Psychiatry (1995) 0.77
Effects of combination of irbesartan and perindopril on calcineurin expression and sarcoplasmic reticulum Ca2+-ATPase activity in rat cardiac pressure-overload hypertrophy. J Zhejiang Univ Sci B (2006) 0.76
Thyroid hormone suppresses expression of stathmin and associated tumor growth in hepatocellular carcinoma. Sci Rep (2016) 0.75
Minimal breast cancer: evaluation of histology and biological marker expression. Br J Cancer (1999) 0.75
Sensitive and reliable PCR and sequencing used to detect p53 point mutations in fine needle aspirates of the breast. J Clin Pathol (1996) 0.75
Biological indices in the assessment of breast cancer. Clin Mol Pathol (1995) 0.75
Mechanism of EGCG promoting apoptosis of MCF-7 cell line in human breast cancer. Oncol Lett (2017) 0.75
Association of epithelial-mesenchymal transition and nuclear cofilin with advanced urothelial cancer. Hum Pathol (2016) 0.75
Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med (2001) 27.70
Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med (1991) 9.99
Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expression in some neoplasms. J Pathol (1990) 5.90
Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med (1997) 4.86
A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med (1987) 3.89
Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med (1995) 3.74
Sepsis syndrome: a valid clinical entity. Methylprednisolone Severe Sepsis Study Group. Crit Care Med (1989) 3.41
Analysis of p53 expression in human tumours: an antibody raised against human p53 expressed in Escherichia coli. J Cell Sci (1992) 3.18
Hypothermia in the sepsis syndrome and clinical outcome. The Methylprednisolone Severe Sepsis Study Group. Crit Care Med (1992) 2.99
Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol (1994) 2.92
Infective endocarditis as part of psittacosis. Lancet (1971) 2.72
Ductal carcinoma in-situ of the breast; second EORTC consensus meeting. Eur J Cancer (1992) 2.67
Eosinophilic infiltrates of the gastrointestinal tract. J Clin Pathol (1986) 2.59
Review: assessment of cell proliferation in histological material. J Clin Pathol (1990) 2.41
Bilateral primary breast cancer: a prospective study of disease incidence. Br J Surg (1984) 2.36
The assessment of proliferating cell nuclear antigen (PCNA) immunostaining in primary gastrointestinal lymphomas and its relationship to histological grade, S+G2+M phase fraction (flow cytometric analysis) and prognosis. Histopathology (1991) 2.32
Atrophy and apoptosis in the cyclical human endometrium. J Pathol (1976) 2.30
Immunohistochemical determination of oestrogen receptor: comparison of different methods of assessment of staining and correlation with clinical outcome of breast cancer patients. Br J Cancer (1996) 2.28
Who needs steroid receptor assays? Lancet (1989) 2.27
Node-negative breast cancer: prognostic subgroups defined by tumor size and flow cytometry. J Clin Oncol (1990) 1.94
Epithelial (E-) and placental (P-) cadherin cell adhesion molecule expression in breast carcinoma. J Pathol (1993) 1.83
Microscopic colitis-a cause of chronic watery diarrhoea. Br Med J (Clin Res Ed) (1982) 1.78
Primary malignant lymphoma of the colon and rectum. A histopathological and immunohistochemical analysis of 45 cases with clinicopathological correlations. Histopathology (1988) 1.76
Microscopic colitis cases revisited. Gastroenterology (1993) 1.74
Oestrogen receptors and the response to endocrine therapy in advanced breast cancer. Br J Cancer (1978) 1.71
Consensus conference definitions for sepsis, septic shock, acute lung injury, and acute respiratory distress syndrome: time for a reevaluation. Crit Care Med (2000) 1.70
Increased use of immunohistochemistry for oestrogen receptor measurement in mammary carcinoma: the need for quality assurance. Eur J Cancer (1998) 1.67
Observer variation and discriminatory value of biopsy features in inflammatory bowel disease. Gut (1994) 1.64
Assessment of axillary lymph node status. Ann Surg (1980) 1.59
New variant Creutzfeldt-Jakob disease: psychiatric features. Lancet (1997) 1.55
Acute ureteric dilatation for ureteroscopy. An experimental study. Br J Urol (1988) 1.53
An immunohistochemical evaluation of c-erbB-2 expression in human breast carcinoma. Br J Cancer (1988) 1.52
The assessment of cellular proliferation by immunohistochemistry: a review of currently available methods and their applications. Histochem J (1992) 1.52
Metastatic carcinoma within the breast. Clin Oncol (1976) 1.51
Contraceptive steroids and breast cancer. Br Med J (1978) 1.51
Mammary hamartoma--a review of 35 cases. Histopathology (1992) 1.50
Immunohistochemistry in district general hospitals in England and Wales. J Clin Pathol (1987) 1.48
A mucocoele-like tumour of the breast associated with both atypical ductal hyperplasia and mucoid carcinoma. Histopathology (1992) 1.47
Collagenous colitis. Gut (1986) 1.47
Carcinoma in situ involving sclerosing adenosis: a mimic of invasive breast carcinoma. Histopathology (1995) 1.46
Prognostic value of proliferating cell nuclear antigen in gastric carcinoma. J Clin Pathol (1991) 1.46
A prospective study of plasma prolactin levels and subsequent risk of breast cancer. Int J Cancer (1981) 1.46
Carcinogenic effects of Di(2-hydroxypropyl)nitrosamine (DHPN) in male Wistar rats: promotion of pancreatic cancer by a raw soya flour diet. Scand J Gastroenterol (1979) 1.44
Early methylprednisolone treatment for septic syndrome and the adult respiratory distress syndrome. Chest (1987) 1.43
Severe recalcitrant erythematous desquamating disorder associated with fatal recurrent toxic shock syndrome in a patient without AIDS. Clin Infect Dis (1997) 1.40
Problems with p53 immunohistochemical staining: the effect of fixation and variation in the methods of evaluation. Br J Cancer (1994) 1.37
Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancer. Eur J Cancer (1981) 1.36
Adenomyoepithelioma of the breast with malignant features. Virchows Arch (1998) 1.35
The effects of long-term feeding of soya flour on the rat pancreas. Scand J Gastroenterol (1980) 1.33
Sclerosing lymphocytic lobulitis of the breast--evidence for an autoimmune pathogenesis. Histopathology (1991) 1.30
p53 represses androgen-induced transactivation of prostate-specific antigen by disrupting hAR amino- to carboxyl-terminal interaction. J Biol Chem (2001) 1.30
One and two view mammography in breast cancer. Are carcinomas detected by one and two view mammography similar? BMJ (1996) 1.30
Diffuse interstitial renal tuberculosis--an unusual cause of renal failure. Q J Med (1981) 1.29
Angiogenesis and inflammation in invasive carcinoma of the breast. J Clin Pathol (1997) 1.26
The Rapid Acute Physiology Score. Am J Emerg Med (1987) 1.24
Overexpression of the c-erbB-2 oncoprotein: why does this occur more frequently in ductal carcinoma in situ than in invasive mammary carcinoma and is this of prognostic significance? Eur J Cancer (1992) 1.24
Breast cancer in women who have taken contraceptive steroids. Br Med J (Clin Res Ed) (1981) 1.22
DNA index, S-phase fraction, histological grade and prognosis in breast cancer. Br J Cancer (1990) 1.21
Evaluation of infiltrating ductal carcinomas with a DCIS component: correlation of the histologic type of the in situ component with grade of the infiltrating component. Semin Diagn Pathol (1994) 1.21
Congenital dilatation of the intrahepatic bile ducts with cholangiocarcinoma. J Clin Pathol (1972) 1.20
Human radiation hepatitis. A morphologic study with emphasis on the late changes. Arch Pathol (1973) 1.20
Different patterns of inflammation and prognosis in invasive carcinoma of the breast. Histopathology (2006) 1.19
Effect of the method of biopsy on the prognosis of and reliability of receptor assays in patients with operable breast cancer. Br J Surg (1986) 1.18
Breast tissue inclusions in axillary lymph nodes. Histopathology (1980) 1.18
The classification of ductal carcinoma in situ and its association with biological markers. Semin Diagn Pathol (1994) 1.18
Angiotropic large cell lymphoma (ALCL): morphological, immunohistochemical and genotypic studies with analysis of previous reports. Hematol Oncol (1989) 1.18
A comparison of proliferating cell nuclear antigen (PCNA) immunostaining, nucleolar organizer region (AgNOR) staining, and histological grading in gastrointestinal stromal tumours. J Pathol (1992) 1.17
Haemangiopericytomas: the prognostic value of immunohistochemical staining with a monoclonal antibody to proliferating cell nuclear antigen (PCNA). Histopathology (1991) 1.17
Histochemical studies with an estrogen receptor-related protein in human breast tumors. Cancer Res (1986) 1.15
Varied light and scanning electron microscopic appearances of barium sulphate in smears and histological sections. J Clin Pathol (1984) 1.15
Prediction of local recurrence of ductal carcinoma in situ of the breast using five histological classifications: a comparative study with long follow-up. Hum Pathol (1998) 1.14
Binding of oestradiol to blood proteins and aetiology of breast cancer. Int J Cancer (1986) 1.14
The clinical evaluation of new drugs for sepsis. A prospective study design based on survival analysis. JAMA (1993) 1.14
Problems in breast pathology. Major Probl Pathol (1979) 1.12
Primary malignant lymphoma of the large intestine complicating chronic inflammatory bowel disease. Histopathology (1989) 1.11
Intercellular spaces and cell junctions in endometrial glands: their possible role in menstruation. Br J Obstet Gynaecol (1977) 1.11
Regulation of human alveolar macrophage inflammatory cytokine production by interleukin-10. Clin Immunol Immunopathol (1996) 1.10
The prognostic value of individual histologic grading parameters in small lingual squamous cell carcinomas. The importance of the pattern of invasion. Cancer (1994) 1.10
Exogenous pigment in Peyer's patches. Hum Pathol (1987) 1.10
Weddellite calcification in the breast: eighteen cases with implications for breast cancer screening. Histopathology (1990) 1.09
c-Jun enhancement of androgen receptor transactivation is associated with prostate cancer cell proliferation. Oncogene (2006) 1.09
Carcinoma of the pancreas. J Pathol (1979) 1.09
Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ. Hum Pathol (1990) 1.08
Interaction of azaserine and raw soya flour on the rat pancreas. Scand J Gastroenterol (1981) 1.07
Acantholytic variant of squamous-cell carcinoma of the breast. Am J Surg Pathol (1986) 1.07
The detection and significance of calcifications in the breast: a radiological and pathological study. Br J Radiol (1976) 1.07
Relative concentrations of endotoxin-binding proteins in body fluids during infection. Lancet (1994) 1.05
Benign lymph node inclusions mimicking metastatic carcinoma. J Clin Pathol (1994) 1.04
Invasive lobular and invasive ductal carcinoma of the breast show distinct patterns of vascular endothelial growth factor expression and angiogenesis. J Pathol (1998) 1.04
Comparison between p53 staining in tissue sections and p53 proteins levels measured by an ELISA technique. Br J Cancer (1993) 1.04
Apocrine carcinoma of the breast. A morphologic and immunocytochemical study. Am J Pathol (1986) 1.03
The effects of chemotherapy on morphology, cellular proliferation, apoptosis and oncoprotein expression in primary breast carcinoma. Br J Cancer (1994) 1.03
Correlation of hormone receptors with pathological features in human breast cancer. Cancer (1980) 1.02
An immunohistological and genotypic study of the plasma cell form of Castleman's disease. Histopathology (1989) 1.02
Use of predicted risk of mortality to evaluate the efficacy of anticytokine therapy in sepsis. The rhIL-1ra Phase III Sepsis Syndrome Study Group. Crit Care Med (1996) 1.02
Histopathology of breast cancer in relation to age. Br J Cancer (1997) 1.01
Renal biopsy in patients with unexplained renal impairment and normal kidney size. Q J Med (1989) 1.00
Systemic herpes simplex infection in a newborn treated with intravenous idoxuridine. Arch Dis Child (1968) 1.00
Cyclin D1 and associated proteins in mammary ductal carcinoma in situ and atypical ductal hyperplasia. J Pathol (1998) 1.00